REPLIGEN CORP Capital Leased Assets, Gross
REPLIGEN CORP (RGEN) had Capital Leased Assets, Gross of $60.51 thousand as of 2014-09-30, per its 10-Q filed 2014-11-07.
Discontinued › Notes › Leases
us-gaap:CapitalLeasedAssetsGross · last filed 2014-11-07
- 2014-09-30: Capital Leased Assets, Gross $60.51K.
- 2014-06-30: Capital Leased Assets, Gross $60.51K.
| Period end | Capital Leased Assets, Gross |
|---|---|
| 2014-09-30 | $60.51K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $60.51K 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |